- ¥770
- Biolegend
- 420601
- 进口
- 2025年07月13日
12 年金牌会员
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存：
现货
- 英文名：
Brefeldin A Solution (1,000X)
- 供应商：
上海善然生物科技有限公司
- 保存条件：
低温
- 规格：
1ml
Brefeldin A Solution (1,000X)
Catalog# / Size 420601 / 1 mL
Other Names BFA
Description Brefeldin A (BFA) is a protein transport inhibitor commonly used to enhance intracellular
cytokine staining signals by blocking transport processes during cell activation. Especially
useful for the intracellular staining of cytokines, BFA leads to the accumulation of most
cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, et al., 1993). Optimal
conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are
included during in vitro cell activation cultures for 4-24 hours prior to harvest (see references
below for additional information). Brefeldin A Solution is supplied as a 1,000X solution,
which should be diluted to 1X in cell culture medium.
Product Details
Formulation Brefeldin A Solution is supplied as a 1000X in DMSO, which should be diluted to 1X in cell culture
medium.
Concentration 5.0 mg/ml
Storage & Handling Store the Brefeldin A Solution (1,000X) between 2°C and 8°C. Note: DMSO freezes at this
temperature.
Application ICFC - Quality tested
Recommended Usage Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are
cultured with brefeldin A for ≤ 24 hours, as this can become toxic for cell viability.
Application Notes Completely thaw the solution before use, DMSO freezes at 4°C. We recommend aliquotting the
reagent into smaller volumes to avoid repeated freeze-thawing.
Application References
(PubMed link indicates
BioLegend citation)
1. O'Sullivan BJ, et al. 2006. J. Immunol. 176:7278.
2. Fuse S, et al. 2007. J. Immunol. 178:5227.
3. Kang YJ, et al. 2007. Nature Immunol. 8:601.
4. Redfern CH,et al.2006.J. Clin Oncol.19:3107. PubMed
5. Smithey MJ, et al. 2008. J. Immunol. 180:3406. PubMed
6. Elzey BD, et al. 2008. Blood 111:38684. PubMed
7. Nguyen KD, et al. 2008. J. Immunol. 181:5386. PubMed
8. Miner MD, et al. 2008. Microb Pathog. 45:273. PubMed
9. Goodridge HS, et al. 2009. J. Immunol. 182:1146. PubMed
10. Markey KA, et al. 2009. Blood 113:5644. PubMed
11. Wilcox RA, et al. 2009. Blood PubMed
12. Zenaro E, et al. 2009. J. Leukoc Bio. PubMed
Product Citations
1. Redfern C, et al. 2006. J Clin Oncol. 24:3107. PubMed
2. Nguyen K, et al. 2008. J Immunol. 181:5386. PubMed
3. Elzey B, et al. 2008. Blood. 111:3684. PubMed
4. Smithey M, et al. 2008. J Immunol. 180:3406. PubMed
5. Zenaro E, et al. 2009. J Leukoc Biol. 86:1393. PubMed
6. Wilcox R, et al. 2009. Blood. 114:2936. PubMed
7. Markey K, et al. 2009. Blood. 113:5644. PubMed
8. Goodridge H, et al. 2009. J Immunol. 182:1146. PubMed
9. Liu W, et al. 2010. J Virol. 84:12011. PubMed
10. Gnerlich J, et al. 2010. J Immunol. 185:4063. PubMed
11. Boisvert M, et al. 2010. J Virol. 84:7782. PubMed
12. Butchar J, et al. 2010. Clin Cancer Res. 2.100694444. PubMed
Antigen Details
Antigen References 1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 Detection of Intracellular
Cytokines by Flow Cytometry (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, et al. 1991. Immunol. Rev. 119:65.
3. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
4. Prussin C, et al. 1995. J. Immunol. Meth. 188:117.
5. Jung T, et al. 1993. J. Immunol. Meth. 159:197.
Version: 1 Revision Date: 11/30/2012
Related Protocols
Intracellular Cytokine Staining Protocol - Video
Intracellular Flow Cytometry Staining Protocol
For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other
violations that may occur with the use of our products.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website,
www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to
manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written
approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.
Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or
commercial use.
BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587
Catalog# / Size 420601 / 1 mL
Other Names BFA
Description Brefeldin A (BFA) is a protein transport inhibitor commonly used to enhance intracellular
cytokine staining signals by blocking transport processes during cell activation. Especially
useful for the intracellular staining of cytokines, BFA leads to the accumulation of most
cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, et al., 1993). Optimal
conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are
included during in vitro cell activation cultures for 4-24 hours prior to harvest (see references
below for additional information). Brefeldin A Solution is supplied as a 1,000X solution,
which should be diluted to 1X in cell culture medium.
Product Details
Formulation Brefeldin A Solution is supplied as a 1000X in DMSO, which should be diluted to 1X in cell culture
medium.
Concentration 5.0 mg/ml
Storage & Handling Store the Brefeldin A Solution (1,000X) between 2°C and 8°C. Note: DMSO freezes at this
temperature.
Application ICFC - Quality tested
Recommended Usage Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are
cultured with brefeldin A for ≤ 24 hours, as this can become toxic for cell viability.
Application Notes Completely thaw the solution before use, DMSO freezes at 4°C. We recommend aliquotting the
reagent into smaller volumes to avoid repeated freeze-thawing.
Application References
(PubMed link indicates
BioLegend citation)
1. O'Sullivan BJ, et al. 2006. J. Immunol. 176:7278.
2. Fuse S, et al. 2007. J. Immunol. 178:5227.
3. Kang YJ, et al. 2007. Nature Immunol. 8:601.
4. Redfern CH,et al.2006.J. Clin Oncol.19:3107. PubMed
5. Smithey MJ, et al. 2008. J. Immunol. 180:3406. PubMed
6. Elzey BD, et al. 2008. Blood 111:38684. PubMed
7. Nguyen KD, et al. 2008. J. Immunol. 181:5386. PubMed
8. Miner MD, et al. 2008. Microb Pathog. 45:273. PubMed
9. Goodridge HS, et al. 2009. J. Immunol. 182:1146. PubMed
10. Markey KA, et al. 2009. Blood 113:5644. PubMed
11. Wilcox RA, et al. 2009. Blood PubMed
12. Zenaro E, et al. 2009. J. Leukoc Bio. PubMed
Product Citations
1. Redfern C, et al. 2006. J Clin Oncol. 24:3107. PubMed
2. Nguyen K, et al. 2008. J Immunol. 181:5386. PubMed
3. Elzey B, et al. 2008. Blood. 111:3684. PubMed
4. Smithey M, et al. 2008. J Immunol. 180:3406. PubMed
5. Zenaro E, et al. 2009. J Leukoc Biol. 86:1393. PubMed
6. Wilcox R, et al. 2009. Blood. 114:2936. PubMed
7. Markey K, et al. 2009. Blood. 113:5644. PubMed
8. Goodridge H, et al. 2009. J Immunol. 182:1146. PubMed
9. Liu W, et al. 2010. J Virol. 84:12011. PubMed
10. Gnerlich J, et al. 2010. J Immunol. 185:4063. PubMed
11. Boisvert M, et al. 2010. J Virol. 84:7782. PubMed
12. Butchar J, et al. 2010. Clin Cancer Res. 2.100694444. PubMed
Antigen Details
Antigen References 1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 Detection of Intracellular
Cytokines by Flow Cytometry (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, et al. 1991. Immunol. Rev. 119:65.
3. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
4. Prussin C, et al. 1995. J. Immunol. Meth. 188:117.
5. Jung T, et al. 1993. J. Immunol. Meth. 159:197.
Version: 1 Revision Date: 11/30/2012
Related Protocols
Intracellular Cytokine Staining Protocol - Video
Intracellular Flow Cytometry Staining Protocol
For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other
violations that may occur with the use of our products.
*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website,
www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to
manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written
approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses.
Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or
commercial use.
BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验相关实验
Intracellular Immunofluorescent Staining for Flow Cytometry
, it is necessary to block secretion of cytokines with protein transport inhibitors, such as Monensin or Brefeldin A , during the last few hours of the stimulation. It is advised that the investigators evaluate the use and efficacy of different protein transport
is lost on tips). Rotate in cold room for 1 hr. Spin and wash beads twice with RIPA (discard supernatant), and then once with Histone Wash Buffer. Add 30 µL of Histone Assay solution. Incubate at 37°C for exactly 30 min. Mix
Th17 Polarization of Mouse CD4 Cells
.#575702] Recombinant human TGF-β1(carrier-free)[Details: Biolengend, cat.#580702] Recombinant mouse IL-23 (carrier-free)[Details: Biolengend, cat.#589002] Brefeldin A[Details: Biolengend, cat.#420601] PdBu(Phorbol12,13
Brefeldin A Solution (1,000X)
¥770
